AGENUS INC APIC, Share-based Payment Arrangement, Increase for Cost Recognition
AGENUS INC (AGEN) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $6.97 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-07
- AGENUS INC apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $6.97M, a 108.96% increase year-over-year.
- AGENUS INC apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $774.00K, a 75.69% decline year-over-year.
- AGENUS INC apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $2.81M, a 69.74% decline year-over-year.
- AGENUS INC apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $3.34M, a 64.07% decline year-over-year.
- AGENUS INC apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $11.62M, a 57.47% decline from fiscal 2024.
- AGENUS INC apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $27.33M, a 22.26% increase from fiscal 2023.
- AGENUS INC apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $22.35M, a 21.51% increase from fiscal 2022.
- AGENUS INC apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $18.39M, a 3.86% decline from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $6.97M 10-Q · filed 2026-08-07 | $7.75M derived: sum of 2 quarters · filed 2026-08-07 | |||
| 2026-03-31 | $774.00K 10-Q · filed 2026-08-07 | ||||
| 2025-12-31 | $11.62M 10-K · filed 2026-03-16 | ||||
| 2025-09-30 | $2.81M 10-Q · filed 2025-11-10 | $6.15M derived: sum of 2 quarters · filed 2026-08-07 | $9.33M derived: sum of 3 quarters · filed 2026-08-07 | ||
| 2025-06-30 | $3.34M 10-Q · filed 2026-08-07 | $6.52M derived: sum of 2 quarters · filed 2026-08-07 | |||
| 2025-03-31 | $3.18M 10-Q · filed 2026-08-07 | ||||
| 2024-12-31 | $27.33M 10-K · filed 2026-03-16 | ||||
| 2024-09-30 | $9.28M 10-Q · filed 2025-11-10 | $18.57M derived: sum of 2 quarters · filed 2025-11-10 | $22.77M derived: sum of 3 quarters · filed 2025-11-10 | ||
| 2024-06-30 | $9.29M 10-Q · filed 2025-11-10 | $13.49M derived: sum of 2 quarters · filed 2025-11-10 | |||
| 2024-03-31 | $4.20M 10-Q · filed 2025-11-10 | ||||
| 2023-12-31 | $22.35M 10-K · filed 2026-03-16 | ||||
| 2023-09-30 | $5.54M 10-Q · filed 2024-11-12 | $11.58M derived: sum of 2 quarters · filed 2024-11-12 | $17.06M derived: sum of 3 quarters · filed 2024-11-12 | ||
| 2023-06-30 | $6.04M 10-Q · filed 2024-11-12 | $11.53M derived: sum of 2 quarters · filed 2024-11-12 | |||
| 2023-03-31 | $5.49M 10-Q · filed 2024-11-12 | ||||
| 2022-12-31 | $18.39M 10-K · filed 2025-03-17 | ||||
| 2022-09-30 | $4.43M 10-Q · filed 2023-11-09 | $9.05M derived: sum of 2 quarters · filed 2023-11-09 | $14.00M derived: sum of 3 quarters · filed 2023-11-09 | ||
| 2022-06-30 | $4.62M 10-Q · filed 2023-11-09 | $9.56M derived: sum of 2 quarters · filed 2023-11-09 | |||
| 2022-03-31 | $4.95M 10-Q · filed 2023-11-09 | ||||
| 2021-12-31 | $19.13M 10-K · filed 2024-03-14 | ||||
| 2021-09-30 | $4.78M 10-Q · filed 2022-11-08 | $10.21M derived: sum of 2 quarters · filed 2022-11-08 | $14.14M derived: sum of 3 quarters · filed 2022-11-08 | ||
| 2021-06-30 | $5.43M 10-Q · filed 2022-11-08 | $9.36M derived: sum of 2 quarters · filed 2022-11-08 | |||
| 2021-03-31 | $3.93M 10-Q · filed 2022-11-08 | ||||
| 2020-12-31 | $10.12M 10-K · filed 2023-03-16 | ||||
| 2020-09-30 | $2.62M 10-Q · filed 2021-11-09 | $5.08M derived: sum of 2 quarters · filed 2021-11-09 | $7.48M derived: sum of 3 quarters · filed 2021-11-09 | ||
| 2020-06-30 | $2.46M 10-Q · filed 2021-11-09 | $4.86M derived: sum of 2 quarters · filed 2021-11-09 | |||
| 2020-03-31 | $2.40M 10-Q · filed 2021-11-09 | ||||
| 2019-12-31 | $9.89M 10-K · filed 2022-03-01 | ||||
| 2019-09-30 | $3.08M 10-Q · filed 2020-11-09 | $5.00M derived: sum of 2 quarters · filed 2020-11-09 | $6.84M derived: sum of 3 quarters · filed 2020-11-09 | ||
| 2019-06-30 | $1.92M 10-Q · filed 2020-11-09 | $3.76M derived: sum of 2 quarters · filed 2020-11-09 | |||
| 2019-03-31 | $1.84M 10-Q · filed 2020-11-09 | ||||
| 2018-12-31 | $7.35M 10-K · filed 2021-03-16 | $7.35M 10-K · filed 2019-03-18 | |||
| 2018-09-30 | $1.91M 10-Q · filed 2019-11-07 | $3.49M derived: sum of 2 quarters · filed 2019-11-07 | $5.42M derived: sum of 3 quarters · filed 2019-11-07 | ||
| 2018-06-30 | $1.58M 10-Q · filed 2019-11-07 | $3.52M derived: sum of 2 quarters · filed 2019-11-07 | |||
| 2018-03-31 | $1.93M 10-Q · filed 2019-11-07 | ||||
| 2017-12-31 | $10.92M 10-K · filed 2020-03-16 | $10.92M 10-K · filed 2018-03-16 | |||
| 2016-12-31 | $13.32M 10-K · filed 2019-03-18 | ||||
| 2015-12-31 | $8.10M 10-K · filed 2018-03-16 | ||||
| 2014-12-31 | $4.60M 10-K · filed 2017-03-16 | ||||
| 2013-12-31 | $4.05M 10-K · filed 2016-03-15 | ||||
| 2012-12-31 | $4.07M 10-K · filed 2015-03-16 | ||||
| 2011-12-31 | $3.34M 10-K · filed 2014-03-07 | ||||
| 2010-12-31 | $2.81M 10-K · filed 2013-03-18 | ||||
| 2009-12-31 | $3.12M 10-K · filed 2012-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |